He noted that in the second phase of clinical trials, "100% vaccine efficacy" was shown.
“And now already 16 thousand people who have been vaccinated in the framework of phase III show the high effectiveness of this vaccine,” Dmitrieva quotes TASS.
In addition, he spoke about plans to supply the vaccine to Latin America.
Dmitriev did not rule out that deliveries could begin in December.
On September 24, it became known that the Gamaleya center launched clinical trials of the Sputnik V vaccine on risk groups.